May 10, 2018 - Halozyme Therapeutics, Inc. (NASDAQ:HALO) has filed a financial statement reporting Increase Decrease In Accounts Payable And Accrued Liabilities of $-12,561,000 USD. Previously, on May 09, 2017, Halozyme Therapeutics, Inc. reported Increase Decrease In Accounts Payable And Accrued Liabilities of $-4,413,000 USD.

Period EndPeriodValue
2018-03-31 2018-Q1 -12561000
2017-03-31 2017-Q1 -4413000
2016-03-31 2016-Q1 -4565000
2015-03-31 2015-Q1 -1209000
2014-03-31 2014-Q1 3,419,000
2013-03-31 2013-Q1 1,980,892
2012-03-31 2012-Q1 -3609171
2011-03-31 2011-Q1 -2771781

Other Interesting Charts

Accrued Outsourced Research And Development Expenses Current - Accrued Outsourced Researchand Development Expenses Long Term - Accruedmanufacturingexpenses - Allocated Share Based Compensation Expense - Costs And Expenses - Current Federal Tax Expense Benefit - Current State And Local Tax Expense Benefit - Deferred Federal Income Tax Expense Benefit - Deferred Foreign Income Tax Expense Benefit - Deferred Revenue - Deferred Revenue Current - Deferred Revenue Noncurrent - Deferred Revenue Relating To Upfront Payment License Fees - Deferred State And Local Income Tax Expense Benefit - Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost - Hypothetical License Revenueunder ASC606 - Hypothetical Royalty Revenueunder ASC606 - Income Tax Expense Benefit - Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items - Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate - Income Tax Reconciliation Nondeductible Expense Other - Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost - Increase Decrease In Deferred Revenue - Increase Decrease In Prepaid Deferred Expense And Other Assets - Interest Expense - License And Services Revenue - Operating Leases Rent Expense Net - Other Noncash Expense - Other Nonoperating Income Expense - Other Prepaid Expense Current - Prepaid Expense And Other Assets - Prepaid Expense And Other Assets Current - Prepaid Expense And Other Assets Noncurrent - Prepaid Expense Current - Recognition Of Deferred Revenue - Research And Development Expense - Revenueamortizationoflicensepayments - Revenues - Royalty Revenue - Sales Revenue Goods Net - Selling General And Administrative Expense - Unrecognized Tax Benefits Income Tax Penalties And Interest Expense - Valuation Allowances And Reserves Charged To Cost And Expense -

Related News Stories

Stocks To Watch: Spotlight On Banks, Google Hardware And IPOs

2018-10-06 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (320-4)

Top Analyst Upgrades and Downgrades: Aetna, Analog Devices, Lowe’s, Merck, Pfizer, Plug Power, Qualcomm, Target and More

2018-08-23 247wallst
Stocks were indicated to open lower on Thursday morning, though the S&P 500 hit an all-time high earlier in the week. Earnings season is all but over now and was quite strong, with more than 70% of the companies exceeding expectations. Despite the gains in the market, 2018 has been choppy, and investors have seen less reward in buying every dip than they had been used to in recent years. Many investors also are trying to decide how they want their investments positioned ahead of the midterm elections and given international trade concerns. (44-1)

A Glimpse into the Pancreatic Cancer Pipeline

2018-08-23 biospace
The passing of singing great Aretha Franklin has focused attention on pancreatic cancer. Franklin, 76, succumbed to a neuroendocrine tumor of the pancreas. According to the National Cancer Institute (NCI), pancreatic cancer is relatively rare, with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases. But each year, 44,330 Americans die from the disease, or about 7. (0-1)

Halozyme: A Look At The Q2 2018 Earnings

2018-08-19 seekingalpha
Halozyme Therapeutics (NASDAQ:HALO) is a robust grower that is operating near its growth inflection. Most investment risks are now significantly deleveraged due to the increasing sales from the approved molecules. Despite that that the partnered products in commercialization are delivering meaningful sales, there are substantial unlocked values in the developing pipeline. In the past 52-week, the stock traded up by $4.

Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks
Halozyme Therapeutics (HALO - Free Report) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. (2-0)

CUSIP: 40637H109